A Randomized, Multicenter Study of Epivir 150 Mg Bid, Retrovir 200 Mg Tid and a Protease Inhibitor Vs 3TC 150 Mg/ZDV 300 Mg Fixed Dose Tablet Given Bid With a Protease Inhibitor in HIV-Infected Patients

Inclusion Criteria Patients must have: HIV infection documented by a licensed antibody ELISA assay and confirmed by Western blot, positive HIV blood culture, positive HIV serum antigen, or plasma viremia. CD4+ cell count of at least 300 cells/mm3. HIV-1 RNA less than 10,000 copies/ml by Roche Amplicor PCR assay. CDC Category A or B Classification for HIV infection (no clinical diagnosis of AIDS). Compliance with dosing schedule and protocol evaluations. Prior Medication: Required: 3TC at 150 mg bid, ZDV at 600 mg/day (200 mg tid or 300 mg bid), plus a marketed protease inhibitor (ritonavir, saquinavir, indinavir, or nelfinavir) at its recommended dose for at least 10 weeks. Allowed: Inhaled corticosteroids for the treatment of asthma. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Malabsorption syndromes affecting drug absorption (e.g., Crohn's disease and chronic pancreatitis). Enrollment in other investigational protocols. Concurrent Medication: Excluded: Cytotoxic chemotherapeutic agents. Nonnucleoside reverse transcriptase inhibitors. Other investigational agents. Concurrent Treatment: Excluded: Radiation therapy. Prior Medication: Excluded: Cytotoxic chemotherapeutic and immunomodulating agents such as systemic corticosteroids, IF-2, alpha-IFN, beta-IFN, or gamma-IFN (except for inhaled corticosteroids for the treatment of asthma) within 4 weeks of study entry. HIV immunotherapeutic vaccine within 3 months of study entry. Prior Treatment: Excluded: Radiation therapy within 4 weeks of study entry.